Literature DB >> 22354785

Role of PRAS40 in Akt and mTOR signaling in health and disease.

Claudia Wiza1, Emmani B M Nascimento, D Margriet Ouwens.   

Abstract

The proline-rich Akt substrate of 40 kDa (PRAS40) acts at the intersection of the Akt- and mammalian target of rapamycin (mTOR)-mediated signaling pathways. The protein kinase mTOR is the catalytic subunit of two distinct signaling complexes, mTOR complex 1 (mTORC1) and mTORC2, that link energy and nutrients to the regulation of cellular growth and energy metabolism. Activation of mTOR in response to nutrients and growth factors results in the phosphorylation of numerous substrates, including the phosphorylations of S6 kinase by mTORC1 and Akt by mTORC2. Alterations in Akt and mTOR activity have been linked to the progression of multiple diseases such as cancer and type 2 diabetes. Although PRAS40 was first reported as substrate for Akt, investigations toward mTOR-binding partners subsequently identified PRAS40 as both component and substrate of mTORC1. Phosphorylation of PRAS40 by Akt and by mTORC1 itself results in dissociation of PRAS40 from mTORC1 and may relieve an inhibitory constraint on mTORC1 activity. Adding to the complexity is that gene silencing studies indicate that PRAS40 is also necessary for the activity of the mTORC1 complex. This review summarizes the regulation and potential function(s) of PRAS40 in the complex Akt- and mTOR-signaling network in health and disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22354785     DOI: 10.1152/ajpendo.00660.2011

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  74 in total

Review 1.  mTOR function and therapeutic targeting in breast cancer.

Authors:  Stephen H Hare; Amanda J Harvey
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  Low Molecular Weight Fraction of Commercial Human Serum Albumin Induces Morphologic and Transcriptional Changes of Bone Marrow-Derived Mesenchymal Stem Cells.

Authors:  David Bar-Or; Gregory W Thomas; Leonard T Rael; Elizabeth D Gersch; Pablo Rubinstein; Edward Brody
Journal:  Stem Cells Transl Med       Date:  2015-06-03       Impact factor: 6.940

3.  Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.

Authors:  Elisa Boscolo; Patricia Pastura; Kathryn Glaser; Jillian Goines; Adrienne M Hammill; Denise M Adams; Peter Dickie; Belinda Hsi Dickie; Timothy D Le Cras
Journal:  Pediatr Blood Cancer       Date:  2019-05-02       Impact factor: 3.167

4.  Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro.

Authors:  Oxana V Denisova; Sandra Söderholm; Salla Virtanen; Carina Von Schantz; Dmitrii Bychkov; Elena Vashchinkina; Jens Desloovere; Janne Tynell; Niina Ikonen; Linda L Theisen; Tuula A Nyman; Sampsa Matikainen; Olli Kallioniemi; Ilkka Julkunen; Claude P Muller; Xavier Saelens; Vladislav V Verkhusha; Denis E Kainov
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

5.  Inherent aerobic capacity-dependent differences in breast carcinogenesis.

Authors:  Henry J Thompson; Lee W Jones; Lauren G Koch; Steven L Britton; Elizabeth S Neil; John N McGinley
Journal:  Carcinogenesis       Date:  2017-09-01       Impact factor: 4.944

6.  Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1α to promote the metastasis of hepatocellular carcinoma.

Authors:  F Hu; X Deng; X Yang; H Jin; D Gu; X Lv; C Wang; Y Zhang; X Huo; Q Shen; Q Luo; F Zhao; T Ge; F Zhao; W Chu; H Shu; M Yao; J Fan; W Qin
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

7.  PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways.

Authors:  Xiaoxing Xiong; Rong Xie; Hongfei Zhang; Lijuan Gu; Weiying Xie; Michelle Cheng; Zhihong Jian; Kristina Kovacina; Heng Zhao
Journal:  Neurobiol Dis       Date:  2014-02-27       Impact factor: 5.996

8.  PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.

Authors:  Michael I Dougherty; Christine E Lehman; Adam Spencer; Rolando E Mendez; Abel P David; Linnea E Taniguchi; Julie Wulfkuhle; Emanuel F Petricoin; Daniel Gioeli; Mark J Jameson
Journal:  Mol Cancer Res       Date:  2020-05-28       Impact factor: 5.852

9.  Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.

Authors:  Magdalena Bieniasz; Parvathi Radhakrishnan; Najme Faham; Jean-Paul De La O; Alana L Welm
Journal:  Clin Cancer Res       Date:  2015-08-19       Impact factor: 12.531

10.  Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.

Authors:  Brittany Knick Ragon; Hagop Kantarjian; Elias Jabbour; Farhad Ravandi; Jorge Cortes; Gautam Borthakur; LaKiesha DeBose; Zhihong Zeng; Heather Schneider; Naveen Pemmaraju; Guillermo Garcia-Manero; Steven Kornblau; William Wierda; Jan Burger; Courtney D DiNardo; Michael Andreeff; Marina Konopleva; Naval Daver
Journal:  Am J Hematol       Date:  2016-12-07       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.